Cargando…

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the seq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerro-Herreros, Estefanía, González-Martínez, Irene, Moreno-Cervera, Nerea, Overby, Sarah, Pérez-Alonso, Manuel, Llamusí, Beatriz, Artero, Rubén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452101/ https://www.ncbi.nlm.nih.gov/pubmed/32805487 http://dx.doi.org/10.1016/j.omtn.2020.07.021

Ejemplares similares

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021)

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models
por: Cerro-Herreros, Estefania, et al.
Publicado: (2018)

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes
por: Cerro-Herreros, Estefania, et al.
Publicado: (2017)

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila
por: Cerro-Herreros, Estefania, et al.
Publicado: (2016)

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA(LR) Mice
por: Overby, Sarah J., et al.
Publicado: (2023)

Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model
por: Bargiela, Ariadna, et al.
Publicado: (2015)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
por: Overby, Sarah J., et al.
Publicado: (2022)

Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
por: González-Martínez, Irene, et al.
Publicado: (2023)

In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models
por: González, Àlex L., et al.
Publicado: (2017)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Two Enhancers Control Transcription of Drosophila muscleblind in the Embryonic Somatic Musculature and in the Central Nervous System
por: Bargiela, Ariadna, et al.
Publicado: (2014)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism
por: Rech, Monika, et al.
Publicado: (2018)

AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm
por: Gangemi, Sebastiano, et al.
Publicado: (2021)

Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
por: Murdaca, Giuseppe, et al.
Publicado: (2019)

Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction
por: Chakraborty, Mouli, et al.
Publicado: (2015)

AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
por: Kazemi, Azam, et al.
Publicado: (2021)

Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease
por: Rapisarda, Anna, et al.
Publicado: (2021)

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model
por: Llamusi, Beatriz, et al.
Publicado: (2013)

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers
por: Fernandez-Costa, Juan M., et al.
Publicado: (2016)

Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia
por: Dorrance, Adrienne M., et al.
Publicado: (2015)

AntagomiR‐29b inhibits vascular and valvular calcification and improves heart function in rats
por: Fang, Ming, et al.
Publicado: (2020)

A novel biologically hierarchical hydrogel with osteoblast precursor‐targeting extracellular vesicles ameliorates bone loss in vivo via the sequential action of antagomiR‐200b‐3p and antagomiR‐130b‐3p
por: Dai, Hanhao, et al.
Publicado: (2023)

Exosomal Delivery of AntagomiRs Targeting Viral and Cellular MicroRNAs Synergistically Inhibits Cancer Angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2020)

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
por: Sellier, Chantal, et al.
Publicado: (2018)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus
por: Guo, Hui, et al.
Publicado: (2023)

Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells
por: McCully, Mark, et al.
Publicado: (2018)

AntagomiR-451 inhibits oxygen glucose deprivation (OGD)-induced HUVEC necrosis via activating AMPK signaling
por: Yang, Xi, et al.
Publicado: (2017)

Enhanced effects of antagomiR-3074-3p-conjugated PEI-AuNPs on the odontogenic differentiation by targeting FKBP9
por: Jiang, Tao, et al.
Publicado: (2023)

Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice
por: Bargiela, Ariadna, et al.
Publicado: (2023)

Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression
por: Sabater-Arcis, Maria, et al.
Publicado: (2021)

Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)

Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus
por: Liu, Xiangwei, et al.
Publicado: (2017)

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2023)

Use of AgomiR and AntagomiR technologies to alter satellite cell proliferation in vitro, miRNA expression, and muscle fiber hypertrophy in intrauterine growth-restricted lambs
por: Greene, M. A., et al.
Publicado: (2023)

Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
por: Espinosa-Espinosa, Jorge, et al.
Publicado: (2022)

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy
por: Sabater-Arcis, Maria, et al.
Publicado: (2019)

Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene
por: Llamusí, Beatriz, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1qtm63vffdjrbibc73oidjrgt8